Analysts believe Abbott (NYSE:ABT) may gain traction on Boston Scientific’s (NYSE:BSX) Watchman in the left atrial appendage closure (LAAC) space.
The second LAAC survey commissioned by SVB Leerink, which compared information from electrophysiologists to information from interventional cardiologists in the previous survey, pointed to the deceleration of Watchman volume expectations from double-digit growth in 2021-2022 down to high-single-digit-growth in 2023, according to analysis.
Analysts say that, although Abbott’s gain of traction in the LAAC space — with the company garnering FDA approval for its Amplatzer Amulet device earlier this month — comes to a lesser extent than Boston Scientific’s, the survey points to faster volume growth at centers adopting both devices and better Boston Scientific market share retention overall.
The surveyed electrophysiologists projected Abbott’s share shift at 18% in 2023 (against 24% share pro…